James “Jim” Jogerst joined Rubius as Chief Business Officer in August of 2021, bringing more than 20 years of experience in developing, structuring and closing high-level deals, including mergers and acquisitions, business development and licensing transactions. As CBO, he leads business development strategy and execution, including strategic partnerships, collaborations and alliances that align with Rubius’ overall corporate strategy.
Jim joins Rubius most recently from Janssen Pharmaceuticals, where he led licensing transactions in the company’s Infectious Diseases and Vaccines business. Before that, Jim spent nearly ten years at Alcon, Inc., where he developed and executed business development and licensing and mergers and acquisitions strategy for Alcon’s three global franchises: surgical, pharmaceutical and vision care. Earlier in his career Jim held executive positions in several investment banking boutiques in Dallas after starting his career in consulting with Arthur Andersen.
Jim has an MBA in Finance and International Business from Pepperdine University and a BA in Economics and Political Science from the University of North Texas. He also holds the Chartered Financial Analyst (“CFA”) designation.